High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic results

References

• Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11: 5–14
   PubMed Web of Science ®Google Scholar
• Bertino JR. Clinical use of methotrexate with emphasis on use of high doses. Cancer Treat Rep 1981; 65(Suppl 1)131–5
   PubMedGoogle Scholar
• Graf N, Winkler K, Betlemovic M, Fuchs N, Bode U. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994; 12: 1443–51
   PubMed Web of Science ®Google Scholar
• Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G. High dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 1997; 61: 779–83
   Google Scholar
• Ferrari S, Sassoli V, Orlandi M, Strazzari S, Puggioli C, Battistini A, et al. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 1993; 5: 135–41
   PubMed Web of Science ®Google Scholar
• Djerassi I, Farber S, Abir E, Neikirk W. Continuous infusion of methotrexate in children with acute leukemia. Cancer 1967; 20: 233–42
   PubMed Web of Science ®Google Scholar
• Jaffe N. Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 1972; 30: 1627–31
   PubMed Web of Science ®Google Scholar
• Rosen G, Suwansirikul S, Kwon C, Tan C, Wu SJ, Beattie EJ, Jr, et al. High dose methotrexate with citrovorum factor rescue and adriamicyn in childhood osteogenic sarcoma. Cancer 1974; 33: 1151–63
   PubMed Web of Science ®Google Scholar
• Frei E, 3rd, Jaffe N, Tattersall MH, Pitman S, Parker L. New approaches to cancer chemotherapy with methotrexate. N Engl J Med 1975; 292: 846–51
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, et al. Predictive factors of histological response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high dose methotrexate, doxorubicin and cisplatin. J Clin Oncol 1998; 16: 658–63
   PubMed Web of Science ®Google Scholar
• Delepine N, Delepine G, Jasmin C, Desbois JC, Cornille H, Mathe G. Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. Biomed Pharmacother 1988; 42: 257–62
   PubMedGoogle Scholar
• Gorlick R, Meyers P, Kellick M, Bertino JR. Monitoring methotrexate levels in osteosarcoma. J Clin Oncol 1998; 16: 2290–1
   PubMedGoogle Scholar
• Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420–4
   PubMed Web of Science ®Google Scholar
• Raude E, Oellerich M, Weinel P, Freund M, Schrappe C, Riehm H, et al. High dose methotrexate: pharmacokinetics in children and young adults. Intl J Clin Pharmacol Ther Toxicol 1988; 26: 364–70
   PubMedGoogle Scholar
• Bacci G, Ferrari S, Bertoni F, Rueeieri P, Picci P, Longhi A, et al. Long-term outcome for patients with non-metastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to IOR/Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000; 18: 4016–27
   PubMed Web of Science ®Google Scholar
• Shargel, L, Yu, A. Applied biopharmaceutics & pharmacokinetics. Appleton & Lange, New York 1999.
   Google Scholar
• Food and Drug Administration. Guidance for Industry Population Pharmacokinetic. U.S. Dept. of Health, Rockville 1999.
   Google Scholar
• Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977; 101: 14–8
   PubMed Web of Science ®Google Scholar
• Rousseau A, Sabot C, Delepine N, Delepine G, Debord J, Lachatre G, et al. Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma. Clin Pharmacokinet 2002; 41: 1095–104
   PubMed Web of Science ®Google Scholar
• Jaffe N, Link MP, Cohen D, Traggis D, Frei E, 3rd, Wattis H, et al. High dose methotrexate in osteogenic sarcoma. NCI Monogr 1981; 56: 201–6
   Google Scholar